Selective G Protein-coupled Receptor Kinase 5 Inhibitors for Treatment of Heart Disease and Cancer

  • TRL
  • 2

Abstract
Purdue University researchers have developed a series of compounds for the treatment of cardiovascular disease and cancer. These compounds target GRK5, a G protein-coupled receptor linked to progressive heart failure, hypertrophic cardiomyopathy, and cancer. Currently, there are no FDA-approved GRK5 inhibitors for treatment of these diseases. The Purdue compounds and their derivatives were specifically designed to target GRK5, they are highly potent selective and reversibly inhibit GRK5 with a half maximal inhibitory concentration in the nanomolar range. This current class of compounds has high therapeutic potential in the treatment of heart disease and cancer. Advantages: -Highly potent and selective GRK5 inhibitors -Reversible mechanism of action -Compounds and their derivatives have favorable drug properties Applications: -Cardiovascular disease treatment -Cancer treatment -Drug discovery

Contact Information

Name: Joseph R Kasper

Email: JRKasper@prf.org

Phone: 765-588-3475